Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anhui Anke Biotechnology (Group) Co., Ltd. (300009.SZ)
Hefei, CN
Anhui Anke Biotechnology (Group) Co., Ltd. is engaged in the research, manufacturing, and global distribution of pharmaceutical goods, serving both domestic Chinese and international markets. Its flagship offerings include Ansomone, a brand of recombinant human growth hormone administered via injection, and the Anterferon line, which comprises recombinant human interferon alpha 2b in various forms such as lyophilized powder, liquid, and prefilled syringes for injection, alongside creams, eye drops, and suppositories. The company also supplies an array of diagnostic kits, including those for detecting anti-sperm antibodies, performing semen leukocyte peroxidase staining, single-use semen processing, sperm hypo-osmotic staining, assessing sperm viability, analyzing sperm morphology, determining sperm acrosin levels, identifying sperm DNA fragmentation, and for leptin and immunohistochemical analyses. Furthermore, their product portfolio extends to adhesive bandages, liquid oral medications, various topical formulations (including creams and ointments), active pharmaceutical ingredients (APIs) derived from peptides, cosmetic and anti-aging treatments, and synthetic pharmaceutical compounds available as powders, dripping pills, and both tablets and capsules. Moreover, Anke Biotechnology offers genetic testing solutions, encompassing kits for autosomal, sex chromosome, and combined autosomal and sex chromosome analyses, along with complete paternity testing packages. They also develop biological immunotherapy treatments for tumors and provide specialized DNA testing services. Established in 2000, the firm's headquarters are situated in Hefei, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.22% | +1.09% | -5.88% | -16.97% | -15.79% | -13.06% | -6.52% | -17.95% | -47.17% | +8.47% | +167.52% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | +1 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+4.4% ★ Q1'26: -13.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+4.8% Q1'26: -23.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+26.8% ★ Q1'26: +23.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+31.6% ★ Q1'26: +34.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+22.6% ★ Q1'26: +19.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.7% ★ Q1'26: +2.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.03× ★ Q1'26: 0.08× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
635.76M
est: 697.50M (-8.9%)
|
849.22M
est: 849.00M (+0.0%)
|
1.10B
est: 1.08B (+1.3%)
|
1.46B
est: 1.38B (+5.8%)
|
1.71B
est: 1.74B (-1.7%)
|
1.70B
est: 2.05B (-17.1%)
|
2.17B
est: 2.21B (-1.7%)
|
2.33B
est: 2.82B (-17.3%)
|
2.87B
est: 2.84B (+1.1%)
|
2.54B
est: 2.68B (-5.3%)
|
2.65B
est: 2.68B (-1.1%)
|
2.91B
2.91B – 2.91B
+8.8% YoY
|
3.17B
3.17B – 3.17B
+8.8% YoY
|
3.50B
3.50B – 3.50B
+10.3% YoY
|
| EBITDA |
174.75M
est: 226.40M (-22.8%)
|
261.78M
est: 275.58M (-5.0%)
|
355.17M
est: 351.13M (+1.1%)
|
395.01M
est: 448.27M (-11.9%)
|
461.82M
est: 565.65M (-18.4%)
|
462.67M
est: 666.37M (-30.6%)
|
676.71M
est: 715.89M (-5.5%)
|
836.21M
est: 915.03M (-8.6%)
|
993.44M
est: 920.22M (+8.0%)
|
846.07M
est: 1.06B (-20.5%)
|
959.03M
est: 1.06B (-9.9%)
|
1.16B
1.16B – 1.16B
+8.8% YoY
|
1.26B
1.26B – 1.26B
+8.8% YoY
|
1.39B
1.39B – 1.39B
+10.3% YoY
|
| EBIT |
147.79M
est: 202.51M (-27.0%)
|
216.32M
est: 246.50M (-12.2%)
|
302.20M
est: 314.08M (-3.8%)
|
338.85M
est: 400.97M (-15.5%)
|
399.46M
est: 505.96M (-21.0%)
|
396.69M
est: 596.05M (-33.4%)
|
599.30M
est: 640.34M (-6.4%)
|
755.70M
est: 818.47M (-7.7%)
|
912.92M
est: 823.11M (+10.9%)
|
759.46M
est: 912.57M (-16.8%)
|
835.09M
est: 912.57M (-8.5%)
|
992.51M
992.51M – 992.51M
+8.8% YoY
|
1.08B
1.08B – 1.08B
+8.8% YoY
|
1.19B
1.19B – 1.19B
+10.3% YoY
|
| Net Income |
136.25M
est: 182.41M (-25.3%)
|
197.30M
est: 215.40M (-8.4%)
|
277.74M
est: 294.80M (-5.8%)
|
263.17M
est: 327.30M (-19.6%)
|
124.47M
est: 222.99M (-44.2%)
|
358.96M
est: 434.82M (-17.4%)
|
206.63M
est: 563.88M (-63.4%)
|
703.26M
est: 757.44M (-7.2%)
|
847.23M
est: 841.61M (+0.7%)
|
706.95M
est: 701.77M (+0.7%)
|
735.19M
est: 751.90M (-2.2%)
|
810.38M
810.38M – 810.38M
+7.8% YoY
|
902.28M
902.28M – 902.28M
+11.3% YoY
|
1.02B
1.02B – 1.02B
+13.0% YoY
|
| SGA |
295.80M
est: 277.99M (+6.4%)
|
399.25M
est: 338.37M (+18.0%)
|
458.66M
est: 431.14M (+6.4%)
|
729.84M
est: 550.41M (+32.6%)
|
794.21M
est: 694.53M (+14.4%)
|
772.81M
est: 818.20M (-5.5%)
|
928.18M
est: 879.01M (+5.6%)
|
860.56M
est: 1.12B (-23.4%)
|
1.02B
est: 1.13B (-9.8%)
|
978.30M
est: 948.57M (+3.1%)
|
617.09M
est: 948.57M (-34.9%)
|
1.03B
1.03B – 1.03B
+8.8% YoY
|
1.12B
1.12B – 1.12B
+8.8% YoY
|
1.24B
1.24B – 1.24B
+10.3% YoY
|
| EPS |
0.10
est: 0.11 (-10.0%)
|
0.13
est: 0.13 (+1.6%)
|
0.18
est: 0.18 (+2.8%)
|
0.17
est: 0.19 (-12.6%)
|
0.08
est: 0.13 (-42.6%)
|
0.22
est: 0.26 (-14.8%)
|
0.13
est: 0.34 (-61.2%)
|
0.43
est: 0.45 (-4.4%)
|
0.52
est: 0.50 (+4.0%)
|
0.42
est: 0.42 (+0.0%)
|
0.44
est: 0.45 (-2.2%)
|
0.49
0.49 – 0.49
+7.8% YoY
|
0.54
0.54 – 0.54
+11.3% YoY
|
0.61
0.61 – 0.61
+13.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-26 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-25 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-21 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-20 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-19 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-18 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-15 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-14 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-13 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 2/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-15 | A- | 4/5 | 4/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 101.5K | 0.19% |
| 2 | Franklin FTSE China ETF FLCH | 0.01% | 16.0K | 0.19% |
| 3 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 13.4K | 0.44% |
| 4 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 179.1K | 0.06% |
| 5 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 120.4K | 0.29% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 37.1K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 16.4K | 0.48% |
| 8 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 1.83M | 0.06% |
| 9 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 77.4K | 0.39% |
| 10 | Vanguard FTSE All-World High Dividend Yield UCITS ETF (USD) Accumulating VHYA.L | 0.00% | 106.5K | 0.29% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chenghao Hu | Financial Director & Accounting Supervisor | — | male |
| Chunyan Lu | Vice President | — | female |
| Hai Sheng | Senior Vice President | — | male |
| Hongyi Yao | Vice President | — | female |
| Hui Zhao | Senior Vice President & Director | — | female |
| Jian Ping Yao | Senior Vice President | — | male |
| Kun Li | Secretary of the Board & Director | — | male |
| Lihua Song | Chairman of Board of Directors & President | — | male |
| Xian Yu Du | Director | — | male |
| Xueke Bao | Vice President | — | male |
| Yinghui Dou | Vice President | — | male |
| Yong Bin Wang | Director of Operations & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300009.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
